Notably, NCOA2 has been detected as a fusion partner in numerous other malignancies, including acute myeloid leukaemia (MYST3-NCOA2) (42), other types of acute leukaemia (ETV6-NCOA2) (43), subtypes of alveolar rhabdomyosarcoma (PAX3-NCOA2) (44) and, recently, benign soft tissue angiofibromas (AHHR-NCOA2) (45). This evidence concerns the gene NCOA2 and rhabdomyosarcoma.